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Effect of Subconjunctivally Injected, Liposome-Bound,
Low-Molecular-Weight Heparin on the Absorption Rate
of Subconjunctival Hemorrhage in Rabbits
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Ho-Kyung Choung,5 and Jeong-Min Hwang1,6
PURPOSE. To investigate the effect of subconjunctival injection
of liposome-bound, low-molecular-weight heparin (LMWH) on
the absorption rate of subconjunctival hemorrhages.
METHODS. Subconjunctival hemorrhages were induced in both
eyes of 30 rabbits by the subconjunctival injection of 0.1 mL of
autologous blood from auricular marginal veins. After 8 hours,
randomized subconjunctival injections of one of three materi-
als were made: 5 IU/mL liposome-bound LMWH (0.1 mL) in 18
eyes (group A), only liposomes (0.1 mL) in 14 eyes (group B),
the free form of LMWH (5 IU/mL, 0.1 mL) in 14 eyes (group C),
or no injection in 14 eyes (group D). Subconjunctival hemor-
rhages were photographed with a digital camera at 8, 24, 48,
72, 96, and 120 hours after induction of subconjunctival hem-
orrhages, sized with an image analyzer, and compared between
groups.
RESULTS. Subconjunctival hemorrhages were absorbed faster in
group A (liposome-bound LMWH injected) than in with group
B (liposome injected). Comparison of groups A and C (free
LMWH injected) showed statistical differences in the absorp-
tion rates at 96 and 120 hours except at 24, 48, and 72 hours.
The mean elapsed time for the complete resorption of subcon-
junctival hemorrhages was shortest in group A among four
groups, whereas group B and the control showed no signifi-
cant differences. The ocular and systemic absorption of LMWH
were significantly lower after injection of the liposome-bound
than the free form.
CONCLUSIONS. The subconjunctival injection of liposome-bound
LMWH appears to enhance subconjunctival hemorrhage ab-
sorption in rabbits. (Invest Ophthalmol Vis Sci. 2006;47:
3968–3974) DOI:10.1167/iovs.05-1345
Subconjunctival hemorrhage is exposed to view and can betroublesome from a cosmetic perspective. However, few
therapeutic trials have been attempted to enhance its absorp-
tion,1 and ophthalmologists tend to disappoint patients by
advising that they wait until absorption occurs spontaneously.
Low molecular weight heparin (LMWH) produced from
chemical or enzymatic hydrolytic cleavage of unfractionated
heparin is an antithrombotic drug with an apparent molecular
weight in the range of 3 to 9 kDa. LMWH is an improved
anticoagulant compared with unfractionated heparin with re-
spect to a longer half-life, higher bioavailability, less bleeding
propensity, and less binding to non–anticoagulant-related
plasma proteins and platelets.2 It inhibits thrombin and thus
suppresses the cascade of reactions that lead to blood clotting
and the formation of a fibrin meshwork in vitro and in vivo.
Thus, it could prevent clots from becoming larger and causing
more serious problems in such conditions as ischemic heart
disease and acute pulmonary embolism.3,4
Although it is generally believed that heparin does not
dissolve blood clots that have already been formed, there have
been several reports regarding the fibrinolysis-enhancing ef-
fects of heparin.2,5–7 Heparin prevents the formation of stable
fibrin clots by inhibiting the activation of fibrin stabilizing
factor.2 The administration of LMWH is known to induce the
release of antiplatelet substances like prostacyclin, and of fi-
brinolytic activators such as tissue plasminogen activator, the
latter of which converts plasminogen into plasmin and acti-
vates several matrix metalloproteinases.5–7 It has been also
reported that fibrinolysis may be suppressed by thrombin.7
Considering these antithrombotic and fibrinolysis-enhanc-
ing activities of heparin, it is possible that the subconjunctival
application of heparin affects the absorption of subconjuncti-
val hemorrhage. However, as heparin has a narrow therapeutic
range, the subconjunctival applicability of LMWH is limited by
the potential risk of systemic and ocular side effects. Lipo-
somes may be an appropriate ocular drug delivery system to
overcome these limitations, as subconjunctival liposomes may
be related to the sustained release and retentive effects at the
site of injection of the encapsulated drug.8,9
The present scenario is full of opportunities in this regard,
as it may be that controlled-release of liposome-bound LMWH
would be helpful in the absorption of subconjunctival hemor-
rhages. Few studies have been conducted to investigate the
possibility. We investigated the effect of liposome-bound
LMWH on the absorption rate of subconjunctival hemorrhages.
MATERIALS AND METHODS
The lipids of liposomes, 1,2-dioleoyl-3-trimethylammonium-propane
(chloride salt, DOTAP, 99%) and cholesterol, were purchased from
Avanti Polar Lipids Inc. (Birmingham, AL). LMWH (80 IU/mg, 7 kDa)
was from Daihan Pharmaceutical Co. (Seoul, South Korea). Fifty-four
New Zealand White rabbits, weighing 2.0 to 3.0 kg, were used in the
study. All experimental methods and animal care procedures con-
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Preparation and Size Measurement of
Liposome-Bound LMWH
Liposome-bound LMWH was prepared by hydration of a lipid film with
a drug solution, as previously described, with slight modification in a
single large batch.10 Briefly, cholesterol and DOTAP were dissolved in
2 mL of chloroform at a molar ratio of 1:1. The solvent was removed
under reduced pressure at 50 °C to 60°C in a rotary evaporator (model
RE-121; Büchi Labortechnik, Essen, Germany) to leave a thin lipid film
on a round-bottomed flask. Residual organic solvent was removed by
flushing with nitrogen for 1 hour. Sterile saline containing LMWH (80
IU/mg, 7 kDa) at a concentration of 10 IU/mL was added to the film
to create 2% (wt/vol) lipid suspension. After vigorous vortexing for 1
hour, the resultant liposomes were sonicated in a bath type sonicator
(Branson Ultrasonic Co. Danbury. CT) for 1 hour at room temperature
and extruded (Avestin Co., Ottawa, ON, Canada) twice through poly-
carbonate membranes (Nuclepore; Whatman, Clifton, NJ), once at a
pore size of 1 m followed by 200 nm, under nitrogen pressure (300
kPa). After extrusion, the liposomal suspension was mixed with 0.02%
of benzalkonium chloride (preservative) and stored at 4°C. The mean
size of the liposome-bound LMWH was 546  41.94 nm (n  5).
Evaluation of In Vitro Release of LMWH
from Liposomes
The liposome-bound LMWH formulations were placed in a closed vial
and immersed in a shaking water bath at 37°C. At 24, 48, 72, 96, and
120 hours after preparation of liposome-bound LMWH, the in vitro
release rate of LMWH from liposomes was determined by separating
liposomes from the suspension medium by ultracentrifugation (Optima
TLX ultracentrifuge; Beckman, Fullerton, CA) in a rotor (TLA 100.3;
Beckman) at room temperature, 150,000g for 90 minutes.11 Then, the
supernatant was removed and replaced with the same quantity of
sterile saline for subsequent analysis. LMWH content in the superna-
tant was determined by a modified colorimetric method (Azure II;
Sigma-Aldrich, St. Louis, MO) at each interval.12 The cumulative release
rate was defined as follows: (C/T)  100 (%), where C is the cumulative
amount of LMWH detected only in the supernatant, and T is the total
amount of LMWH in liposome formulations.
Induction of Subconjunctival Hemorrhages
General anesthesia was achieved intramuscularly with 30 to 45 mg/kg
of ketamine hydrochloride and 5 to 10 mg/kg of xylazine hydrochlo-
ride and topical anesthesia with proparacaine hydrochloride. Autolo-
gous blood sampled from the auricular marginal vein was subconjunc-
tivally injected into both eyes of all rabbits (0.1 mL, 1 to 2 mm from the
superior limbus) with a 1-mL syringe and 30-gauge needle with the
bevel down. Every effort was made to avoid any vascular injury at the
ocular surface.
Grouping
Eight hours after induction of subconjunctival hemorrhages, the mate-
rial to be injected for each eye of 30 rabbits was assigned by block
randomization: group A (18 eyes): 0.1 mL of liposome-bound LMWH (5
IU/mL); group B (14 eyes): 0.1 mL of liposomes; group C (14 eyes): 0.1
mL of the free form of LMWH (5 IU/mL); and group D: (14 eyes): no
injection. Block randomization was performed by selecting blindly one
of cards, on which were written the names of material to be injected.
A preliminary experiment demonstrated no significant effects on the
absorption rate of subconjunctival hemorrhages in the fellow un-
treated eyes after treatment of one eye with liposome-bound or free
form LMWH, thus allowing use of both eyes simultaneously. The
participants, who performed block randomization, subconjunctival
injections, and measurement of the sizes of subconjunctival hemor-
rhages, were blind to the types of the injected materials.
Measurement of the Subconjunctival
Hemorrhage Size
Subconjunctival hemorrhage was photographed with a digital camera
(Coolpix 950; Nikon, Tokyo, Japan) at 8, 24, 48, 72, 96, and 120 hours
after the hemorrhage induction. The digital camera was positioned
perpendicular to the center of the lesion at a fixed distance (21 cm)
and magnification (125). A translucent bar, 5  2 mm2 in size marked
with 1-mm graduations, was placed onto the central area of subcon-
junctival hemorrhage as a reference for sizing (Fig. 1).
A prominent subconjunctival bleb was produced by injecting au-
tologous blood, and this enlarged and flattened after 4 to 5 hours of the
induction. Therefore, the sizes of subconjunctival hemorrhages at 8
hours after induction were defined as basal levels. The digitalized
images of subconjunctival hemorrhages were sized using an image
analyzer (Image Pro-Plus, ver. 3.0.1; Media Cybernetics, Silver Spring,
MD).
Evaluation of the Absorption Rates of
Subconjunctival Hemorrhage
Two parameters were used for the evaluation of the absorption rates of
subconjunctival hemorrhages. One of these parameters was the
amount of decrease in the size of the subconjunctival hemorrhage from
baseline size (i.e., the size of the hemorrhage at 8 hours after the
induction), which were compared between groups at 24, 48, 72, 96,
and 120 hours after induction of the hemorrhages. In addition, the
mean elapsed times required for the complete absorption of subcon-
junctival hemorrhages were compared among groups.
Evaluation of Ocular and Systemic Absorption
and Intraocular Side Effects of LMWH
The remaining 24 rabbits were used for the following experiments.
Eight hours after induction of subconjunctival hemorrhages in one eye
of each rabbit (24 eyes) as described earlier, subconjunctival injection
of liposome-bound LMWH (12 rabbits) or the free form of LMWH (12
rabbits) was randomly performed. Slit lamp and fundus examinations
were performed after pupil dilation with 1% tropicamide and 2.5%
phenylephrine hydrochloride eye drops before and at 24, 48, 72, and
120 hours after subconjunctival hemorrhage induction with subse-
quent liposome-bound or free LMWH injection. The developments of
corneal or lens opacity and inflammation or hemorrhage in the anterior
FIGURE 1. Measurement of the size of a subconjunctival hemorrhage.
A translucent 5  2-mm2 bar, marked off in 1 mm, was placed on a
subconjunctival hemorrhage. A photograph was taken with a digital
camera positioned normally from the center of the lesion at a fixed
distance (21 cm) and magnification (125). Lesion sizes were calcu-
lated with an image analyzer.
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chamber and vitreous were evaluated. Then, three rabbits randomly
chosen from each group at 24, 48, 72, and 120 hours after subcon-
junctival hemorrhage induction were killed for the measurement of
LMWH activity in the plasma and ocular tissues of the treated and
fellow untreated eyes. After anesthesia with intramuscular injection of
ketamine hydrochloride and xylazine hydrochloride, 5 mL of blood
was sampled from a marginal auricular vein and centrifuged. The
concentration of LMWH in plasma was determined by a LMWH color-
imetric plasma assay with a sensitivity of 0.1 to 1 IU/mL (Coatest;
Chromogenix Ins., Milano, Italy).
The rabbits were then killed with an overdose of intravenous
pentobarbital sodium and the eyes enucleated. To evaluate the ocular
absorption of LMWH in the treated and fellow untreated eyes, the
anticoagulant activities in the various ocular tissues such as aqueous
humor, vitreous, and a piece of conjunctiva and sclera adjacent to the
injection site were measured. Briefly, aqueous taps (0.1–0.2 mL) were
performed with a 1-mL syringe with 30-gauge needle via a limbal
paracentesis site. After a circumferential full-thickness incision through
the sclera and choroid was made 2.5 mm from the limbus, the vitreous
body was harvested by expression. In addition, a piece of conjunctiva
and sclera (5  5 mm2) around the injection site were removed. The
harvested tissues were kept in tubes at 70°C for subsequent analysis.
The amounts of LMWH in sclera, conjunctiva, and vitreous were
determined by cutting the tissues into small pieces. The tissues were
pooled in a 1.5-mL tube (Eppendorf, Fremont, CA), containing 0.5 mL
of pH 7.4 phosphate-buffered saline and 0.5 mL of 10% Triton X-100.
The tubes were sonicated for 30 minutes, vortexed for 1 hour, and
centrifuged for 30 minutes at 10,000g to extract LMWH from the
tissues. The amounts of LMWH extracted from the tissues and aqueous
were determined with a modified colorimetric method (Azure II; Sigma
Aldrich).12
Statistical Analysis
All continuous variables were expressed as the mean  SD. The
differences in the amount of size decreases of subconjunctival hemor-
rhages between groups were tested with repeated-measures ANOVA.
The baseline sizes and mean elapsed times for the complete resorption
of subconjunctival hemorrhages were compared with one-way
ANOVA. Post hoc pair-wise comparisons adjusted by the Bonferroni-
Dunn method were performed among four groups. As we regarded
two eyes of each rabbit as independent subjects, cluster effects was
not taken into consideration for statistical analysis. Systemic and ocular
absorptions of LMWH were compared by Mann-Whitney test. The level
of significance was considered to be P  0.05.
RESULTS
In Vitro Release Rate of LMWH from Liposomes
The cumulative release rate of LMWH from liposomes is pre-
sented in Figure 2. The release of LMWH from liposomes was
sustained throughout the study.
Size Decrease of Subconjunctival Hemorrhages
The size decreases of the subconjunctival hemorrhages are
presented in Table 1. The baseline sizes (SD) of subconjunc-
tival hemorrhages (measured at 8 hours after the hemorrhage
induction) were 77.98  6.26, 77.18  8.66, 79.95  6.35, and
77.61  7.49 mm2 in groups A, B, C, and D, respectively,
which showed no significant differences among all groups
(P  0.750). The size decreases in the four groups along all
points studied were significantly different (F  6.21, P 
0.001). Post hoc pair-wise multiple comparisons adjusted by
the Bonferroni-Dunn method are presented in Table 2. The size
decreases of the subconjunctival hemorrhages were not similar
among the four groups at 48, 72, 96, and 120 hours, but were
similar at 24 hours. The size decreases of subconjunctival
hemorrhages occurred significantly faster in group A (lipo-
some-bound LMWH) than in group B (liposomes only) through-
out the study, except at 24 hours after the induction (P 
0.617, 0.042, 0.001, 0.0001, and 0.0001 for 24, 48, 72, 96,
and 120 hours, respectively; Table 2). Comparison of the de-
creases in size of hemorrhage in groups A and C (free LMWH)
showed that they were significantly larger in group A (lipo-
some-bound LMWH) at 96 and 120 hours (P  0.011 and 0.001
for 96 and 120 hours, respectively), whereas there were no
differences at 24, 48, and 72 hours (P  0.976, 0.592, and
0.074 for 24, 48, and 72 hours, respectively; Table 2).
There were no significant differences in size decreases of
subconjunctival hemorrhages between groups B and D (no
injection) throughout the study (P  0.950, 0.614, 0.325,
0.715, and 0.744 at 24, 48, 72, 96, and 120 hours, respectively;
Table 2).
Elapsed Time for Complete Resorption of
Subconjunctival Hemorrhages
The mean elapsed times (SD) for the complete resorption of
subconjunctival hemorrhage were 134.44  10.16, 184.29 
30.72, 163.71  19.18, and 188.57  21.27 hours for group A,
B, C, and D, respectively, and were not similar among the four
groups (F  22.525, P  0.001). Post hoc pair-wise compari-
sons adjusted by the Bonferroni-Dunn method revealed that
the mean time for group A was the shortest among the four
groups, whereas there was no significant difference between
groups B and D (Fig. 3).
The mean elapsed time for group A was the shortest among
the four groups. Group C was next. Mean times for complete
resorption of subconjunctival hemorrhages of groups B and D
were similar and delayed the most.
FIGURE 2. The cumulative rate of in vitro release of LMWH from
liposome formulation at 24, 48, 72, 96, and 120 hours after its prepa-
ration. Data are expressed as the mean  SD. The results suggests that
LMWH sustained its release from the liposomes throughout the study
(n  5).
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Ocular and Systemic Absorption and Intraocular
Side Effects of LMWH
The LMWH concentrations in the aqueous humor and vitreous
of eyes treated with free LMWH were significantly higher than
those treated with liposome-bound LMWH at 24 and 48 hours
(P  0.028 at 24 hours and 0.003 at 48 hours for aqueous
humor; P  0.036 at 24 hours and 0.001 at 48 hours for
vitreous). Then, the activities of LMWH in the vitreous of eyes
treated with free LMWH decreased to the level of no significant
differences compared with those treated with liposome-bound
LMWH at 72 and 120 hours (P  0.375 at 72 hours and 0.428
at 120 hours for aqueous humor; P  0.129 at 72 hours and
0.289 at 120 hours for vitreous; Figs. 4A, 4B).
The LMWH activities were significantly higher in the con-
junctiva and sclera at 24 and 48 hours (P  0.017 and 0.008,
respectively, for conjunctiva; P  0.034 and 0.023, respec-
tively for sclera) after free LMWH injection compared with
those after liposome-bound LMWH (Figs. 4C, 4D). Then, the
activity in the conjunctiva and sclera were significantly lower
in eyes treated with free LMWH, whereas sustained activity
was shown with liposome-bound LMWH at 72 and 120 hours
(P  0.017 at 72 hours and 0.009 at 120 hours for conjunctiva;
P  0.021 at 72 hours and 0.011 at 120 hours for sclera).
Systemic absorption after treatment with liposome-bound
LMWH was significantly less at 24 and 48 hours compared with
that after free form of LMWH (P  0.37 and 0. 45, respectively;
Fig. 4E).
There were no detectable LMWH in the fellow untreated
eyes (aqueous, vitreous, conjunctiva, and sclera) after subcon-
junctival injection of liposome-bound or free LMWH through-
out the study.
Slit lamp and fundus examinations revealed no evidences of
opacities in the cornea or lens and inflammations or hemor-
rhages in the anterior chamber and vitreous before and at 24,
48, 72, and 120 hours after subconjunctival hemorrhage induc-
tion with subsequent injection of liposome-bound or free form
of LMWH.
DISCUSSION
The results of our study suggest that subconjunctival injection
of liposome-bound LMWH enhances the rate of subconjuncti-
val hemorrhage resorption steadily with less intraocular or
systemic absorption, although the free form of LMWH retained
this effect in the relatively early phases, but not in the later
phases. The mechanisms by which LMWH facilitated the re-
sorption of subconjunctival hemorrhages might be explained
as follows. First, thrombin-activatable fibrinolysis inhibitor
(TAFI) is the precursor of an exopeptidase that is identical with
plasma procarboxypeptidase B.7 On activation by thrombin,
activated TAFI attenuates fibrinolysis, presumably by catalyzing
the removal of C-terminal lysines from partially degraded fibrin.
Thus, as inhibitors of TAFI activation may enhance thrombol-
ysis,13 anti-thrombin III activity of LMWH would be expected
to enhance the resorption of subconjunctival hemorrhage.
Second, LMWH-induced lipase activity may also enhance sub-
conjunctival hemorrhage resorption.14 Because the plasma
membrane of red blood cell is composed of a lipid bilayer, any
local increase in lipase activity would accelerate red blood cell
degradation. Third, LMWH is known to sequester fibroblast
growth factor 2 (FGF2) in the extracellular environment,
which upregulates urokinase-type plasminogen activator (uPA)
TABLE 1. Size Decreases of Subconjunctival Hemorrhages
Time
(h) Group A Group B Group C Group D
24 7.19  4.84 5.19  3.95 7.24  3.89 5.01  3.48
48 18.98  5.25 12.41  7.67 20.97  6.88 10.44  4.65
72 34.50  10.73 22.24  14.69 27.58  6.08 18.32  8.84
96 47.19  12.99 29.95  21.66 37.28  10.25 28.54  10.12
120 59.39  10.27 37.23  22.02 46.69  10.47 35.97  10.03
Data are expressed as the mean (mm2)  SD.






24 48 72 96 120
A B 0.617 0.042* 0.001* 0.0001* 0.0001*
C 0.976 0.592 0.074 0.011* 0.001*
D 0.570 0.026* 0.0001* 0.0001* 0.0001*
B C 0.542 0.036* 0.192 0.272 0.151
D 0.950 0.614 0.325 0.715 0.744
C D 0.574 0.009* 0.022* 0.131 0.238
Data are probabilities obtained with repeated-measures ANOVA. The subconjunctival hemorrhages
decreased in size significantly faster in group A (liposome-bound LMWH) than in group B (liposomes only)
throughout the study, except at 24 hours after induction. Comparison of groups A and C (free LMWH)
showed were significantly larger decreases in group A (liposome-bound LMWH) at 96 and 120 hours, with
no differences at 24, 48, and 72 hours.
* P  0.05.
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and matrix metalloproteinase (MMP) production in vascular
endothelial cells.15 Thus, blood resorption may be enhanced
because uPA converts plasminogen into plasmin and activates
several MMPs which participate in extracellular matrix degra-
dation.6,16 Fourth, endothelial modulation by LMWH has been
reported to induce the release of fibrinolytic activators such as
tissue plasminogen activator and antiplatelet substances like
prostacyclin.5 Finally, clot retraction, during which the con-
tractile force is transmitted via platelet glycoprotein IIb/IIIa
receptors that bind the polymerized fibrin network to the actin
cytoskeletons of platelets, is known to make blood clots more
resistant to fibrinolysis.17 In view of these relations, it might be
speculated that the suppression of fibrin meshwork formation
by LMWH makes blood clots more susceptible to fibrinolysis.
As shown in Table 2, the thrombolysis-enhancing effect of
free LMWH held on only in the early phases of this study (at 24,
48, and 72 hours after the induction of hemorrhage), however,
no longer in the later phases (at 96 and 120 hours) compared
with that of liposome-bound LMWH. In a perspective of dose–
response relationship, these findings correspond well with the
results that the LMWH activity in conjunctival and sclera adja-
cent to the injection site was significantly higher at 24 and 48
hours after hemorrhage induction with a subsequent decline in
activity, whereas liposome-bound LMWH maintained its local
activity through sustained release from liposomes throughout
the study (Figs. 4C, 4D). Local retention of liposome-bound
LMWH and its sustained release from liposomes are most likely
to be the causes of maintaining local LMWH activity in the
conjunctival and sclera.
Ideal ocular LMWH delivery systems for the purpose of this
study should not only enhance the focal retention and sus-
tained release, but should also prevent systemic side effects
and the ocular toxicity of LMWH. Moreover, the sustained
release and local retention of LMWH is imperative due to a
narrow therapeutic index of LMWH (0.6–1.0 IU/mL) to over-
come the risks for high initial LMWH concentrations at the site
of injection and the drainage of LMWH to systemic circulation,
FIGURE 3. Post hoc groupings after comparison of the mean elapsed
times for the complete resorption of subconjunctival hemorrhages
among the four study groups. The mean elapsed time for group A was
shortest among the four groups, followed by group C, and, then groups
B and D. Data are expressed as the mean  SD. *†‡The group(s) is(are)
different from the rest.
FIGURE 4. Comparison of the concentrations of LMWH in aqueous humor (A), vitreous (B), conjunctiva (C), sclera (D), and plasma (E) between
eyes treated with liposome-bound LMWH and eyes with the free form of LMWH at 24, 48, 72, and 120 hours after subconjunctival hemorrhage
induction. Data are expressed as the mean  SD. *P  0.05.
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which may cause side effects such as bleeding, thrombocyto-
penia, hypersensitivity reactions, and osteoporosis.18 Lipo-
somes work well in this context, as intraocular (aqueous and
vitreous) and systemic absorption of LMWH was considerably
less in group A (liposome-bound LMWH) than group C (free
LMWH) in our study (Figs. 4A, 4B, 4E). This may be explained
as follows. First, the large size of the liposomes ensures that
they remain localized at the injection site.19 This explains why
there was significantly lower LMWH activity in the aqueous
and vitreous of eyes treated with liposome-bound LMWH
(group A) compared with the free form of LMWH (group C) in
our study (Fig. 4A, 4B). Although intraocular side effects were
not detectable in either group, lower intraocular absorption
may be desirable because of the potential risk of side effects.
Ambati et al.20 demonstrated that scleral permeability declines
exponentially with increasing molecular radius (from 0.5 to
8.25 nm) and that molecular radius is a better predictor of
scleral permeability than is molecular weight. It may be possi-
ble that because of the large molecular radius of the liposomes
used in our study (546  41.94 nm), it could not be introduced
into intraocular region, thus resulting in intrascleral entrap-
ment as presented in Figure 4D. In addition, the molecules,
with a molecular mass of 4 to 150,000 D, were found to diffuse
across the sclera in a manner consistent with porous diffusion
through a fiber matrix.20 Consequently, high LMWH activity in
the aqueous and vitreous of eyes treated with free LMWH
injection, with a mass of 7000 D in our study, should be
attributed to the feasibility of transscleral penetration of free
LMWH.
Second, liposomes may block lymphatic and other drainage
pathways, and thereby retard the rate of free drug clear-
ance.21,22 This, along with sustained release of LMWH from
liposomes,8,9 explains in part why there was less systemic
LMWH activity after liposome injection (Fig. 4E).
Third, the positively charged liposomes used in this study
enable loading of large doses of drug, and increase the drug
residence time and concentration for adsorption at the target
sites, according to studies by Law and Hung.10 In the previous
work, the stability and the entrapment efficiency of LMWH-
containing liposomes were greatly influenced by the liposomal
surface charge. The positively charged liposomes showed
higher stability and entrapment efficiency than the neutral or
negatively charged ones.23
Although topical application of liposomes was feasible in
this study, subconjunctival injection of liposomes was reported
to provide effective therapy through directly targeting the site
of action and facilitate the slow, steady release of the encap-
sulated drug, thus allowing a high drug concentration at the
desired site for a long-lasting time.8 Moreover, the main benefit
of a subconjunctival route would be the improved compliance
of patients, because topical preparations can require frequent
administration.
LMWH has some significant advantages over unfractionated
heparins for the purpose of this study. First, a longer half-life by
two- to fourfold.2 Compared with the short (approximately 1.5
hours) and variable half-life of unfractionated heparin,24
LMWH has a longer and more consistent half-life.24,25 The
disappearance times of antifactor Xa and antithrombin activity
of LMWHs have been reported to be longer than 16 hours.26
These findings may explain in part the sustained effect of
liposome-bound LMWH. Second, LMWH administration is as-
sociated with a lower bleeding propensity, as the anti-Xa to
anti-thrombin inhibition ratios of unfractionated heparin and
LMWH are 1:1 and 2 to 4:1, respectively.2,25 The less tendency
of LMWH to induce hemorrhage is another reason that we
selected LMWH instead of unfractionated heparin in this study.
There are a few limitations in this study. First, as we did not
consider the curvature of the rabbit eyes, the size measure-
ment through picturing the lesions on the ocular surface may
not reflect the actual size. To minimize this error, we tried to
picture right above the center of the hemorrhagic lesion at a
fixed distance and magnification with a reference ruler. Sec-
ond, the subconjunctival concentration of LMWH was not
checked. The lack of this data may prevent the direct associa-
tion between the subconjunctival application of LMWH and its
effect at the site. The absorption amount of LMWH after sub-
conjunctival injection in the conjunctiva and sclera may reflect
its subconjunctival concentration. Third, as the subconjuncti-
val hemorrhages in our model were contrived, the action of
liposome-bound LMWH on spontaneous cases remains unde-
termined.
In conclusion, our findings suggest that the subconjunctival
injection of liposome-bound LMWH enhances the absorption
of subconjunctival hemorrhage in rabbit eyes, and could be
useful for treating subconjunctival hemorrhage.
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